Matrix Protein 2 Extracellular Domain-Specific Monoclonal Antibodies Are an Effective and Potentially Universal Treatment for Influenza A-Reference-Cited by-同舟云学术

Matrix Protein 2 Extracellular Domain-Specific Monoclonal Antibodies Are an Effective and Potentially Universal Treatment for Influenza A

Published:2021-02-10 Issue:5 Volume:95 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Bimler Lynn¹²³,Ronzulli Sydney L.⁴,Song Amber Y.¹³,Johnson Scott K.⁴,Jones Cheryl A.⁴,Kim Teha⁵,Le Duy T.¹²³,Tompkins S. Mark⁴^ORCID,Paust Silke¹²³⁵^ORCID

Affiliation:

1. Center for Human Immunobiology, Department of Pediatrics, Texas Children’s Hospital, Houston, Texas, USA

2. Graduate Program in Immunology, Baylor College of Medicine, Houston, Texas, USA

3. Developing Investigative Scholar’s Program (DISP), Rice University, Houston, Texas, USA

4. Center for Vaccines and Immunology, University of Georgia. Athens, Georgia, USA

5. Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA

Abstract

Despite a seasonal vaccine and multiple therapeutic treatments, influenza A remains a significant threat to human health. The biggest obstacle in producing a vaccine or treatment for influenza A is their universality or efficacy against not only seasonal variances in the influenza virus but also all human, avian, and swine serotypes and, therefore, potential pandemic strains.

Funder

The Albert and Margaret Alkek Foundation

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/JVI.01027-20

Reference67 articles.

1. Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines

2. The Pathology of Influenza Virus Infections